Survival Duration and Influencing Factors in Cervical Cancer Patients in Tigray, Ethiopia: A Retrospective Analysis - Top-Institutions - MDSpire

Survival Duration and Influencing Factors in Cervical Cancer Patients in Tigray, Ethiopia: A Retrospective Analysis

  • By

  • Gerezgiher Buruh Abera

  • Mussie Alemayehu

  • Demisew Amenu Sori

  • Rahma Ali

  • Nega Jibat

  • Wondimagegn Adissu

  • Haftamu Hailekiros

  • Endashaw Nadew

  • Ashenafi Alemu

  • Alemseged Abdissa

  • Nigisti Mulholland

  • Gelila K Goba

  • Eva J Kantelhardt

  • Kim Mulholland

  • Prisha Balgovind

  • Gerald L. Murray

  • Suzanne M. Garland

  • March 2, 2026

  • 0 min

Share

Top Institutions in Obgyn

Brief introduction explaining scope and methodology.

  • #1

    MD Anderson Cancer Center
    MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Gynecologic Oncology
    • Cancer Epidemiology
    • Global Oncology

  • #2

    Fred Hutchinson Cancer Center
    Fred Hutchinson Cancer Center

    Seattle, WA

    Key Differentiators

    • Cancer Epidemiology
    • Infectious Disease Oncology
    • Global Health

  • #3

    University of Cape Town
    University of Cape Town

    Cape Town, Western Cape

    Key Differentiators

    • Gynecologic Oncology
    • Public Health
    • Global Oncology

  • #4

    Johns Hopkins University
    Johns Hopkins University

    Baltimore, MD

    Key Differentiators

    • Gynecologic Oncology
    • Global Health
    • Cancer Epidemiology

  • #5

    Addis Ababa University
    Addis Ababa University

    Addis Ababa, Oromia

    Key Differentiators

    • Gynecologic Oncology
    • Public Health
    • Cancer Epidemiology

Original Source(s)

Survival Duration and Influencing Factors in Cervical Cancer Patients in Tigray, Ethiopia: A Retrospective Analysis

  • by Gerezgiher Buruh Abera, Mussie Alemayehu, Demisew Amenu Sori, Rahma Ali, Nega Jibat, Wondimagegn Adissu, Haftamu Hailekiros, Endashaw Nadew, Ashenafi Alemu, Alemseged Abdissa, Nigisti Mulholland, Gelila K Goba, Eva J Kantelhardt, Kim Mulholland, Prisha Balgovind, Gerald L. Murray, Suzanne M. Garland

  • March 2, 2026

Related Content

Tumor-localized CD40 agonism with MP0317, a FAP x CD40 DARPin, reprograms the tumor microenvironment in patients with advanced solid tumors: an open-label, nonrandomized, dose-escalation phase 1 study

Validation of a cervical CDO1/CELF4 methylation test for endometrial cancer: a prospective paired-sample comparison with intrauterine specimen

CKAP2L promotes endometrial cancer progression by suppressing AKT ubiquitination and activating the PI3K/AKT signaling pathway